NLS Pharmaceutics (NLSP) Competitors $1.66 +0.01 (+0.61%) As of 10:35 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock NLSP vs. MIRA, MTVA, MBRX, ALVR, NNVC, AYTU, CASI, ALLR, CTXR, and SNYRShould you be buying NLS Pharmaceutics stock or one of its competitors? The main competitors of NLS Pharmaceutics include MIRA Pharmaceuticals (MIRA), MetaVia (MTVA), Moleculin Biotech (MBRX), AlloVir (ALVR), NanoViricides (NNVC), Aytu BioPharma (AYTU), CASI Pharmaceuticals (CASI), Allarity Therapeutics (ALLR), Citius Pharmaceuticals (CTXR), and Synergy CHC (SNYR). These companies are all part of the "pharmaceutical products" industry. NLS Pharmaceutics vs. Its Competitors MIRA Pharmaceuticals MetaVia Moleculin Biotech AlloVir NanoViricides Aytu BioPharma CASI Pharmaceuticals Allarity Therapeutics Citius Pharmaceuticals Synergy CHC MIRA Pharmaceuticals (NASDAQ:MIRA) and NLS Pharmaceutics (NASDAQ:NLSP) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk. Is MIRA or NLSP more profitable? NLS Pharmaceutics' return on equity of 0.00% beat MIRA Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets MIRA PharmaceuticalsN/A -406.70% -328.44% NLS Pharmaceutics N/A N/A N/A Do analysts prefer MIRA or NLSP? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MIRA Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00NLS Pharmaceutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Do institutionals & insiders hold more shares of MIRA or NLSP? 35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. 6.7% of MIRA Pharmaceuticals shares are owned by insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has stronger earnings & valuation, MIRA or NLSP? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMIRA PharmaceuticalsN/AN/A-$7.85M-$0.49-3.07NLS PharmaceuticsN/AN/A-$1.98MN/AN/A Does the media refer more to MIRA or NLSP? In the previous week, MIRA Pharmaceuticals had 3 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 6 mentions for MIRA Pharmaceuticals and 3 mentions for NLS Pharmaceutics. MIRA Pharmaceuticals' average media sentiment score of -0.09 beat NLS Pharmaceutics' score of -0.33 indicating that MIRA Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MIRA Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral NLS Pharmaceutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, MIRA or NLSP? MIRA Pharmaceuticals has a beta of 1.69, indicating that its stock price is 69% more volatile than the S&P 500. Comparatively, NLS Pharmaceutics has a beta of 0.14, indicating that its stock price is 86% less volatile than the S&P 500. SummaryMIRA Pharmaceuticals and NLS Pharmaceutics tied by winning 4 of the 8 factors compared between the two stocks. Get NLS Pharmaceutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NLSP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NLSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NLSP vs. The Competition Export to ExcelMetricNLS PharmaceuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.94M$2.63B$6.15B$10.65BDividend YieldN/A57.79%5.72%4.83%P/E RatioN/A23.5329.4627.43Price / SalesN/A780.59588.58130.02Price / CashN/A27.2425.8230.35Price / Book-4.495.3412.316.66Net Income-$1.98M$33.06M$3.33B$276.74M7 Day Performance-6.21%0.14%1.98%0.56%1 Month Performance-18.63%8.42%8.24%3.53%1 Year Performance-68.68%-4.43%60.01%36.26% NLS Pharmaceutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NLSPNLS PharmaceuticsN/A$1.66+0.6%N/A-68.9%$5.94MN/A0.006Short Interest ↑Gap DownMIRAMIRA Pharmaceuticals0.3671 of 5 stars$1.30+0.8%N/A+47.3%$24.70MN/A-2.642Gap DownMTVAMetaVia1.6307 of 5 stars$1.01+1.9%$7.50+642.6%N/A$24.44MN/A0.008News CoverageGap UpMBRXMoleculin Biotech1.6974 of 5 stars$0.49+4.6%$4.00+718.0%-80.3%$24.21MN/A0.0020ALVRAlloVirN/A$4.76+7.0%N/A-74.0%$24.01MN/A-0.24110High Trading VolumeNNVCNanoViricides0.836 of 5 stars$1.33-2.2%N/A+1.4%$23.18MN/A-1.8520News CoverageShort Interest ↓Gap DownAYTUAytu BioPharma3.2924 of 5 stars$2.31-1.3%$9.17+296.8%+0.0%$22.89M$66.38M-0.82160CASICASI Pharmaceuticals3.5526 of 5 stars$1.83-3.4%$4.00+119.1%-68.8%$22.46M$28.54M-0.63180ALLRAllarity Therapeutics2.2062 of 5 stars$1.54+0.3%$9.25+502.6%-16.8%$22.36MN/A0.0010Gap DownCTXRCitius Pharmaceuticals2.6193 of 5 stars$1.30-0.4%$53.00+3,992.7%-85.2%$22.03MN/A0.0020Gap UpSNYRSynergy CHC4.34 of 5 stars$2.32+4.0%$10.00+331.0%N/A$21.90M$34.83M6.1140Positive NewsShort Interest ↓Gap Up Related Companies and Tools Related Companies MIRA Pharmaceuticals Alternatives MetaVia Alternatives Moleculin Biotech Alternatives AlloVir Alternatives NanoViricides Alternatives Aytu BioPharma Alternatives CASI Pharmaceuticals Alternatives Allarity Therapeutics Alternatives Citius Pharmaceuticals Alternatives Synergy CHC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NLSP) was last updated on 10/20/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredThis Crypto Is Set to Explode in JanuaryCurious about crypto but still stuck scrolling endless threads? People who get in early aren’t just lucky—they...Crypto 101 Media | SponsoredElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredThe 7 Warning Signals Flashing Red Right NowA free report revealing the 7 key indicators that have predicted every major economic collapse since 1929. ...American Alternative | SponsoredThis dark force is about to change everythingSomething unusual is unfolding inside the Republican Party — from Marjorie Taylor Greene breaking ranks to Ted...Porter & Company | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NLS Pharmaceutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NLS Pharmaceutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
